Destiny Pharma PLC Director/PDMR Shareholding (4546P)

TIDMDEST

RNS Number : 4546P

Destiny Pharma PLC

10 October 2023

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Director/PDMR Shareholding

Brighton, United Kingdom - 10 October 2023 - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that it was notified on 9 October 2023 that on that same day, Chris Tovey, Chief Executive Officer of the Company, purchased 40,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price

of   48.5 pence. 

Following the purchase, Mr. Tovey's beneficial interest in the Company is 40,000 Ordinary Shares, representing 0.04 per cent. of the total issued share capital.

For further information, please contact:

Destiny Pharma plc

Chris Tovey, CEO

Shaun Claydon, CFO

[phone]

[e-mail]

   Cavendish Capital Markets Limited   (Nominated Adviser and Joint Broker) 

Geoff Nash / George Dollemore, Corporate Finance

Nigel Birks / Harriet Ward, ECM

[phone]

   Shore Capital   (Joint Broker) 

Daniel Bush / James Thomas / Lucy Bowden

[phone]

Powerscourt Group

Sarah Macleod / Adam Michael / Ollie Simmonds / Christopher Ward

[phone]

[e-mail]

About Destiny Pharma

Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.

   For further information on the Company, please visit   www.destinypharma.com 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1.   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                               Chris Tovey 
     ---------------------------------  ----------------------------- 
 2.   Reason for the Notification 
     ---------------------------------------------------------------- 
 a)   Position/status                    Chief Executive Officer 
     ---------------------------------  ----------------------------- 
 b)   Initial notification/Amendment     Initial notification 
     ---------------------------------  ----------------------------- 
 3.   Details of the issuer, emission allowance market 
       participant, auction platform, auctioneer or auction 
       monitor 
     ---------------------------------------------------------------- 
 a)   Name                               Destiny Pharma plc 
     ---------------------------------  ----------------------------- 
 b)   LEI                                213800O9WH9Z38EHAC95 
     ---------------------------------  ----------------------------- 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place 
       where transactions have been conducted 
     ---------------------------------------------------------------- 
 a)   Description of the                 Ordinary shares of 1 pence 
       Financial instrument,              each 
       type of instrument 
      Identification code                DEST GB00BDHSP575 
     ---------------------------------  ----------------------------- 
 b)   Nature of the transaction          Purchase of Ordinary Shares 
     ---------------------------------  ----------------------------- 
 c)   Price(s) and volume(s)              48.5 pence 
                                           40,000 Ordinary Shares 
     ---------------------------------  ----------------------------- 
 d)   Aggregated information: 
       Aggregated volume                   See 4c) above 
       Price 
     ---------------------------------  ----------------------------- 
 e)   Date of the transaction            9 October 2023 
     ---------------------------------  ----------------------------- 
 f)   Place of the transaction           London Stock Exchange, AIM 
                                          market (XLON) 
     ---------------------------------  ----------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFVVIALAIIV

(END) Dow Jones Newswires

October 10, 2023 02:00 ET (06:00 GMT)